AstraZeneca: Enhertu demonstrated strong, durable responses in DESTINY-Lung02

Results from the primary analysis of the DESTINY-Lung02 Phase II trial showed Enhertu continued to demonstrate strong and durable tumour responses in previously treated patients with HER2-mutant unresectable and/or metastatic non-squamous non-small cell lung cancer, or NSCLC, AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) reported. These results, along with the first report on progression-free survival, or PFS, and overall survival, or OS, were presented at the International Association for the Study of Lung Cancer, or IASLC, 2023 World Conference on Lung Cancer and simultaneously published in the Journal of Clinical Oncology, the companies announced. At the primary analysis, a confirmed objective response rate of 49.0% and 56.0% was seen in the 5.4mg/kg arm and 6.4mg/kg arm respectively, as assessed by blinded independent central review. The safety profile for both doses was consistent with the overall safety profile of Enhertu, with the 5.4mg/kg dose demonstrating a favourable safety profile in this patient population. Secondary endpoint data were also encouraging, with Enhertu demonstrating a median PFS of 9.9 months and 15.4 months in the 5.4mg/kg and 6.4mg/kg arms respectively, as assessed by BICR. A median OS of 19.5 months was achieved in the 5.4mg/kg arm and not reached in the 6.4mg/kg arm at time of analysis.